Pharmaceuticals News and Research

RSS

Dr. Reddy's gains access to Aegis' Intravail drug delivery technology for undisclosed therapeutics

Dr. Reddy's Laboratories (NYSE: RDY) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Dr. Reddy's access to Aegis' Intravail® drug delivery technology for certain undisclosed therapeutics currently being marketed with annual worldwide sales in excess of U.S. $1 billion. Financial terms were not disclosed.

25 Jan 2010

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced final data from a randomized, controlled Phase 2 trial of picoplatin in metastatic colorectal cancer (CRC) patients.

24 Jan 2010

Renowned heart specialists to discuss new cardiovascular treatment and patient care at public forum

World-leading cardiovascular specialists, researchers, family physicians and the public will learn what's new in cardiovascular treatment, patient care and research at the second annual Peter Munk Cardiovascular Symposium, Partnerships in Integrative Patient Care, on January 29 and 30 at the Toronto Metropolitan Hotel.

23 Jan 2010

PhRMA funds a two-year research initiative to evaluate the safety and benefits of existing drugs

The Pink Sheet recently reported that the Pharmaceutical Research and Manufacturers of America (PhRMA) and individual drug firms, through the Foundation for the National Institutes of Health, are funding a two-year public/private research initiative to evaluate the safety and benefits of drugs that are currently on the market.

23 Jan 2010

Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial

Biovail Corporation today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd. According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched from Wellbutrin XL® 300 mg, Biovail’s FDA-approved brand of the antidepressant, bupropion hydrochloride, to Budeprion XL, Teva’s generic formulation of the drug. The trial was described in a Dow Jones Newswire article dated December 2, 2009.

22 Jan 2010

Access Pharmaceuticals to sell 2.10M shares in registered direct offering

ACCESS PHARMACEUTICALS, INC., today announced that it has entered into definitive agreements with accredited investors to sell in a registered direct offering an aggregate of 2.10 million shares of its common stock at a price of $3.00 per share for aggregate gross proceeds of $6.3 million.

22 Jan 2010

Progress in Anadys Pharmaceuticals' Phase II study of ANA598 announced

Anadys Pharmaceuticals, Inc. today announced that ANA598 dosing has been completed in the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

22 Jan 2010

BioSyent Pharma receives exclusive rights to manufacture and market Virsani sanitizer in Canada and U.S.

BioSyent Inc. ("BioSyent") announces that its subsidiary BioSyent Pharma Inc. has signed a license and distribution agreement with Notlers for VirsaniTM personal sanitizer.

22 Jan 2010

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

Andrew Witty, Chief Executive of GlaxoSmithKline, today announced a series of new initiatives targeted at further transforming the company's approach to diseases that disproportionately affect the world's poorest countries. His announcements build on commitments made in 2009 to work in partnership, expand access to medicines and encourage new research into neglected tropical diseases.

22 Jan 2010

Shandong Luoxin Pharmacy Stock establishes sponsored ADR facility

Shandong Luoxin Pharmacy Stock Co., Ltd., one of the leading PRC pharmaceutical enterprises, announced that a sponsored, American Depositary Receipt ("ADR") facility has been established with The Bank of New York Mellon. Trading of the ADRs has commenced on 21 January, 2010 EST on the U.S. OTC market's highest tier, OTCQX International, under the symbol SLUXY.

22 Jan 2010

Novo Nordisk on FORTUNE's "100 Best Companies to Work For" list for second consecutive year

Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's list of "100 Best Companies to Work For" 2010. This is the second consecutive year that Novo Nordisk has been recognized with this prestigious award. Novo Nordisk moved up to 25 from 57 in the overall list and is only one of two pharmaceutical/biotechnology companies so honored.

From Novo Nordisk 22 Jan 2010

ACS Chemical Biology report supports zebrafish for drug development

By combining the tools of medicinal chemistry and zebrafish biology, a team of Vanderbilt investigators has identified compounds that may offer therapeutic leads for bone-related diseases and cancer.

22 Jan 2010

DIA Annual EuroMeeting programme in Monaco

The Drug Information Association (DIA) in Europe will host its 22nd Annual EuroMeeting from 8-10 March 2010 in Monaco. The DIA Annual EuroMeeting features more than 110 hot-topic sessions across 13 themes and attracts more than 3,000 professionals from the biopharmaceutical industry, contract service organisations, regulatory agencies, health ministries and academia, as well as patients and students worldwide.

22 Jan 2010

NCPDP announces its upcoming Educational Summit, Health Information Exchange and Pharmacy

The National Council for Prescription Drug Programs (NCPDP), a not-for-profit pharmacy standards development organization, announced its upcoming Educational Summit, Health Information Exchange and Pharmacy, February 2, 2010 in Austin, TX.

22 Jan 2010

Norepinephrine responses to bucindolol influenced by alpha-2C adrenergic receptor genotype

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper “An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure” was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure (http://circheartfailure.ahajournals.org).

22 Jan 2010

TGen holds the promise of a brighter economic future for Scottsdale

TGen Drug Development (TD2) is poised to play a significant role in the expansion of Scottsdale's biomedical industry, fostering new jobs and city revenues, and prompting the creation of more related businesses.

22 Jan 2010

Patheon constructs new pharmaceutical development center in Bourgoin-Jallieu

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today it has begun construction of a new pharmaceutical development center at its existing manufacturing facility in Bourgoin-Jallieu, France.

22 Jan 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value.

22 Jan 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.

22 Jan 2010

Envision Pharmaceutical Services receives high customer satisfaction rating for second consecutive year

The Pharmacy Benefit Management Institute (PBMI) recently released the results of its 2009 Pharmacy Benefit Management Customer Satisfaction Report and Envision Pharmaceutical Services, Inc. received the highest overall customer scores for the second straight year.

22 Jan 2010

Pharmaceuticals News and Research

Dr. Reddy's gains access to Aegis' Intravail drug delivery technology for undisclosed therapeutics

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Renowned heart specialists to discuss new cardiovascular treatment and patient care at public forum

PhRMA funds a two-year research initiative to evaluate the safety and benefits of existing drugs

Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial

Access Pharmaceuticals to sell 2.10M shares in registered direct offering

Progress in Anadys Pharmaceuticals' Phase II study of ANA598 announced

BioSyent Pharma receives exclusive rights to manufacture and market Virsani sanitizer in Canada and U.S.

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

Shandong Luoxin Pharmacy Stock establishes sponsored ADR facility

Novo Nordisk on FORTUNE's "100 Best Companies to Work For" list for second consecutive year

ACS Chemical Biology report supports zebrafish for drug development

DIA Annual EuroMeeting programme in Monaco

NCPDP announces its upcoming Educational Summit, Health Information Exchange and Pharmacy

Norepinephrine responses to bucindolol influenced by alpha-2C adrenergic receptor genotype

TGen holds the promise of a brighter economic future for Scottsdale

Patheon constructs new pharmaceutical development center in Bourgoin-Jallieu

CytRx announces its plans to advance multiple oncology development programs in 2010

NicOx receives EMEA approval for naproxcinod MAA

Envision Pharmaceutical Services receives high customer satisfaction rating for second consecutive year

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence